ADEL, Inc. (주식회사 아델) is a clinical-stage biopharmaceutical company headquartered in Seoul, South Korea, founded in 2016 as a spin-off from the Asan Medical Center / University of Ulsan College of Medicine by Professor Seung-Yong Yoon. ADEL develops antibody therapeutics, companion diagnostics and delivery platforms for Alzheimer's disease and other neurodegenerative conditions. Its lead candidate ADEL-Y01 is a humanized monoclonal antibody selectively targeting tau acetylated at Lysine-280 (acK280), in a global first-in-human Phase 1 study under a US FDA-cleared IND; in December 2025 ADEL granted Sanofi exclusive worldwide rights to ADEL-Y01 in a deal worth up to USD 1.04 billion including an USD 80 million upfront payment. The wider pipeline includes ADEL-Y03 (a beta-2 microglobulin antibody), ADEL-Y04 (an ApoE4-targeting antibody), the ADEL-D01 tau pT217 diagnostic antibody, and two proprietary platforms — BTS (Brain Targeting System) for blood-brain-barrier penetration and ADTAC (Autophagic Degradation Targeting Chimera) for targeted protein degradation. The company is research-and-development driven and sells no software product: it publishes no developer portal, public API, SDK, webhook catalog or machine-readable specification of any kind. Its only web surface is the corporate marketing site at adelpharm.com.
ADEL, Inc. is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Healthcare.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/adel97fd: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: adel97fd
name: ADEL, Inc.
description: 'ADEL, Inc. (주식회사 아델) is a clinical-stage biopharmaceutical company headquartered in Seoul, South Korea, founded
in 2016 as a spin-off from the Asan Medical Center / University of Ulsan College of Medicine by Professor Seung-Yong Yoon.
ADEL develops antibody therapeutics, companion diagnostics and delivery platforms for Alzheimer''s disease and other neurodegenerative
conditions. Its lead candidate ADEL-Y01 is a humanized monoclonal antibody selectively targeting tau acetylated at Lysine-280
(acK280), in a global first-in-human Phase 1 study under a US FDA-cleared IND; in December 2025 ADEL granted Sanofi exclusive
worldwide rights to ADEL-Y01 in a deal worth up to USD 1.04 billion including an USD 80 million upfront payment. The wider
pipeline includes ADEL-Y03 (a beta-2 microglobulin antibody), ADEL-Y04 (an ApoE4-targeting antibody), the ADEL-D01 tau pT217
diagnostic antibody, and two proprietary platforms — BTS (Brain Targeting System) for blood-brain-barrier penetration and
ADTAC (Autophagic Degradation Targeting Chimera) for targeted protein degradation. The company is research-and-development
driven and sells no software product: it publishes no developer portal, public API, SDK, webhook catalog or machine-readable
specification of any kind. Its only web surface is the corporate marketing site at adelpharm.com.'
url: https://raw.githubusercontent.com/api-evangelist/adel97fd/refs/heads/main/apis.yml
x-harvest-source-url: https://equityzen.com/company/adel97fd
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: not-a-software-company
x-founded: '2016'
x-headquarters: Seoul, South Korea
x-industry: Biotechnology / Pharmaceuticals
x-identity-note: The harvest stub carried the placeholder name "Adel97fd", taken verbatim from the EquityZen slug. The 97fd
suffix matches Crunchbase's adel-97fd, and the EquityZen listing page title is "Invest In ADEL Stock"; both resolve to ADEL,
Inc., the Korean Alzheimer's antibody developer at adelpharm.com. EquityZen classifies the company under "Software, Artificial
Intelligence, Data and Analytics", which is a venue mis-tag — EquityZen's own body copy on the same page describes a therapeutics
and diagnostics developer, and every independent source (BioSpace, Fierce Biotech, Korea Biomedical Review, BIO International
Convention, PitchBook, Preqin) records a clinical-stage biopharmaceutical company.
x-domain-note: adelpharm.com (created 2018-05-15, registrar Whois Corp.), adelbio.com (created 2026-08-28, registrar Gabia)
and adelbio.co.kr all resolve to the same Cafe24 origin 183.111.183.82 and share the Cafe24 nameservers ns1/ns2.cafe24.co.kr
and .com, so all three are the same first-party surface. Every host answers HTTP 200 to EVERY path with an identical JavaScript-decryption
WAF interstitial (a slowAES "cupid.js" challenge that sets a CUPID cookie and reloads with ?ckattempt=1), including a random
negative-control path that cannot exist. No path on any host returns a document to a non-browser client. See well-known/adel97fd-well-known.yml.
x-venue-note: The harvest source https://equityzen.com/company/adel97fd is an EquityZen secondary-market listing, not ADEL's
own web presence, and is deliberately NOT wired as the Website pointer (roadmap#56). It is recorded as a SecondaryMarket
property instead.
specificationVersion: '0.23'
created: '2026-09-07'
modified: '2026-09-07'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Healthcare
- Drug Discovery
- Antibody Therapeutics
- Neuroscience
- Alzheimers Disease
- Clinical Trials
- Diagnostics
- South Korea
tags_raw:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Healthcare
- Drug Discovery
- Antibody Therapeutics
- Neuroscience
- Alzheimers Disease
- Clinical Trials
- Diagnostics
- South Korea
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/adel97fd-domain-security.yml
- type: Website
name: ADEL corporate site (English)
url: https://adelpharm.com/en/
- type: SecondaryMarket
name: EquityZen pre-IPO listing (third-party venue, not an ADEL page)
url: https://equityzen.com/company/adel97fd
x-coverage:
state: none
reason: not-a-software-company
detail: ADEL is a clinical-stage antibody developer whose product is a drug, not software — its only web surface is the
adelpharm.com corporate marketing site (company, pipeline, technology, news, contact), and that site sits behind a Cafe24
"cupid.js" JavaScript-decryption WAF that answers HTTP 200 with the same interstitial to all 120 probed paths across all
six first-party hosts, including a random negative-control path, so no document — spec, well-known, llms.txt or agent
card — was retrievable and none is documented to exist.
evidence:
- url: https://adelpharm.com/.well-known/adel97fd-negative-control-7c3e91a2.json
status: 200
- url: https://adelpharm.com/openapi.json
status: 200
- url: https://adelpharm.com/.well-known/agent-card.json
status: 200
- url: https://adelbio.com/llms.txt
status: 200
- url: https://api.github.com/orgs/adelpharm
status: 404
- url: https://equityzen.com/company/adel97fd
status: 200
checked: '2026-09-07'
x-enrichment:
date: '2026-09-07'
status: minimal
artifacts_added: 2
pass: local-v3
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →